Advanced search×

European Neuropsychopharmacology

Print ISSN
Electronic ISSN
Impact factor
Usage rank
Article count
Free count
Free percentage
PDFs via platforms
Sciencedirect, Gale, Ingenta, CSA, Rcgp, and Proquest

  1. Neuropeptide S receptor gene variation modulates anterior cingulate cortex Glx levels during CCK-4 induced panic

    European Neuropsychopharmacology 25(10):1677 (2015) PMID 26235955

    An excitatory-inhibitory neurotransmitter dysbalance has been suggested in pathogenesis of panic disorder. The neuropeptide S (NPS) system has been implicated in modulating GABA and glutamate neurotransmission in animal models and to genetically drive altered fear circuit function and ...
  2. Recurrence rates in bipolar disorder: Systematic comparison of long-term prospective, naturalistic studies versus randomized controlled trials

    European Neuropsychopharmacology 25(10):1501 (2015) PMID 26238969

    Bipolar disorder (BD) is a recurrent, lifelong illness with high risks of disability and excess mortality. Despite many treatment options with demonstrated short-term efficacy, evidence concerning long-term treatment effectiveness in BD remains limited and the relative value of natural...
  3. Second-generation antipsychotics and adiponectin levels in schizophrenia: A comparative meta-analysis

    European Neuropsychopharmacology 25(10):1767 (2015) PMID 26164075

    People with schizophrenia treated with second-generation antipsychotics (SGAs) have lower plasma adiponectin levels, as compared with general population, that may lead to metabolic abnormalities. However, the contribution of different SGAs on adiponectin dysregulation is still unclear....
  4. Long-term use of antipsychotics among community-dwelling persons with Alzheimer׳s disease: A nationwide register-based study

    European Neuropsychopharmacology 25(10):1706 (2015) PMID 26233607

    Antipsychotics are recommended only for short-term treatment of severe behavioral and psychological symptoms of dementia. Our objective was to study the duration of antipsychotic use and factors associated with long-term use (365 days or over) among community-dwelling persons with Alzh...
  5. Benzodiazepines and risk of death: Results from two large cohort studies in France and UK

    European Neuropsychopharmacology 25(10):1566 (2015) PMID 26256008

    Benzodiazepines are widely prescribed for the treatment of anxiety or insomnia, but their impact on mortality is still debated. This study investigated the impact of benzodiazepine use on short term mortality. Exposed-unexposed cohorts were constructed with the Clinical Practice Resear...
  6. Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes: A pharmacoepidemiological-pharmacodynamic study in VigiBase

    European Neuropsychopharmacology 25(10):1556 (2015) PMID 26256010

    Pharmacodynamic mechanisms of diabetes induced by antipsychotic drugs remain unclear, while numerous receptors have been suspected to be involved in the genesis of this Adverse Drug Reaction (ADR). We investigated potential relationships between antipsychotics׳ receptor occupancy (sero...
  7. Baclofen for alcohol dependence: Relationships between baclofen and alcohol dosing and the occurrence of major sedation

    European Neuropsychopharmacology 25(10):1631 (2015) PMID 26095229

    High-dose baclofen, i.e., 300mg/d or more, has recently emerged as a strategy for treating alcohol dependence. The impact that the co-exposure of large amounts of alcohol and baclofen has on sedation is unclear. In a prospective cohort of 253 subjects with alcohol dependence,...
  8. Lifelong disturbance of serotonin transporter functioning results in fear learning deficits: Reversal by blockade of CRF1 receptors

    European Neuropsychopharmacology 25(10):1733 (2015) PMID 26302762

    The inability to associate aversive events with relevant cues (i.e. fear learning) may lead to maladaptive anxiety. To further study the role of the serotonin transporter (SERT) in fear learning, classical fear conditioning was studied in SERT knockout rats (SERT−/−) using fear potenti...
  9. Biomarkers of treatment outcome in schizophrenia: Defining a benchmark for clinical significance

    European Neuropsychopharmacology 25(10):1578 (2015) PMID 26145487

    Emerging data from on imaging and genetic studies have generated interest in “clinically significant” biomarkers to predict response and prognosis. What constitutes “clinical significance” and how a biomarker would reach that threshold are unclear. To develop a benchmark we reviewed di...
  10. Lurasidone and fluoxetine reduce novelty-induced hypophagia and NMDA receptor subunit and PSD-95 expression in mouse brain

    European Neuropsychopharmacology 25(10):1714 (2015) PMID 26256011

    Lurasidone, a novel second-generation antipsychotic agent, exerts antidepressant actions in patients suffering from bipolar type I disorder. Lurasidone acts as a high affinity antagonist at multiple monoamine receptors, particularly 5-HT2A, 5-HT7, D2 and α2 receptors, and as a partial ...